RxDoctor Payments Data

Kent Berquist, MD

Pulmonary Disease · Salina, KSNPI 1134184997

Payments from drug & device makers

$313in general payments, 2019–2025

Across 15 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$120
  • Sanofi$68
  • AstraZeneca$38
  • AbbVie$14
  • Boston Scientific$14
  • Regeneron Healthcare Solutions, Inc.$13
  • plus $46 from 4 others

What the payments were for

  • Food & beverage$19362%
  • Education$12038%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$313 in reported general payments places this provider in the 20th percentile of 92 pulmonary disease providers in Kansas.

See all pulmonary disease providers in Kansas

Medicare billing

Part B allowed, 2024
$132,373
Medicare patients
1,178
Services billed
2,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor13$176,915
OpsumitMacitentan12$153,841
NucalaMepolizumab30$148,507
Trelegy ElliptaFluticasone/Umeclidin/Vilanter201$136,803
Breo ElliptaFluticasone/Vilanterol166$70,818
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr144$65,979
Dupixent SyringeDupilumab13$49,482
Dupixent PenDupilumab12$47,644
Ambrisentan14$39,900
Spiriva HandihalerTiotropium Bromide75$38,729
Pirfenidone27$37,892
Incruse ElliptaUmeclidinium Bromide65$21,741
DuleraMometasone/Formoterol43$21,047
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$18,397
Combivent RespimatIpratropium/Albuterol Sulfate33$17,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$12$460,915662 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$38$37,08193 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 92 pulmonary disease providers in Kansas.

Other pulmonary disease in Salina

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →